The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

For the past several years, the halls of the Las Vegas Convention Center have been lousy with AR/VR/XR smart glasses. While ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration ... approval in the U.S., the company ...

17, 2024 — A new study offers hope for people who are ... DNA Damage Is Key Factor in Age-Related Macular Degeneration Dec. 3, 2024 — A research team has discovered that accumulated DNA ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the ...